Update (August 14): Reuters reports that patients with Ebola are now being treated in DRC with mAb114.
More than a decade after an 1995 Ebola outbreak in Kikwit, Democratic Republic of Congo, researchers found a survivor who still harbored antibodies against the virus. One of those antibodies, mAb114, has since been developed as a drug by the US National Institute of Allergy and Infectious Disease (NIAID), together with the Army Medical Research Institute of Infectious Diseases and the Defense Advanced Research Projects Agency. Although the drug is still in a Phase 1 clinical trial, Reuters reports that DRC officials are prepared to use it to treat patients in the current Ebola outbreak in that country.
The Scientist spoke with NIAID Director Anthony Fauci to learn more about mAb114.
The Scientist: How does mAb114 work?
Anthony Fauci: This is an antibody that is derived from a person who was infected with ...
